ACE2016 + pembrolizumab

ACE2016 + pembrolizumab is a combination therapy that includes ACE2016, an investigational biologic, and pembrolizumab, an FDA-approved humanized IgG4 monoclonal antibody against programmed death 1 (PD-1). Pembrolizumab acts as a checkpoint inhibitor, blocking the PD-1/PD-L1 interaction to enhance anti-tumor T cell responses[3]. ACE2016 is a code name that may correspond to a pipeline biologic or antibody therapeutic, though no public clinical trial or regulatory record specifically defining ACE2016 could be confidently identified; thus, it is almost certainly an experimental therapeutic paired with pembrolizumab in clinical investigation or preclinical research. Pembrolizumab is most commonly indicated and approved for use in multiple malignancies, either alone or in combination regimens, and developed by Merck (MSD outside North America)[1][2][3].

Other names

lambrolizumabACE2016ACE-2016ACE 2016